JP2008518904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518904A5 JP2008518904A5 JP2007538541A JP2007538541A JP2008518904A5 JP 2008518904 A5 JP2008518904 A5 JP 2008518904A5 JP 2007538541 A JP2007538541 A JP 2007538541A JP 2007538541 A JP2007538541 A JP 2007538541A JP 2008518904 A5 JP2008518904 A5 JP 2008518904A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal form
- powder
- pharmaceutical composition
- ray diffraction
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- -1 methylcarbamoyl Chemical group 0.000 claims 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- DOFVDAFLHFASDH-UHFFFAOYSA-N 3-(2-pyridin-2-ylethenyl)-1h-indazole Chemical compound N=1NC2=CC=CC=C2C=1C=CC1=CC=CC=N1 DOFVDAFLHFASDH-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62466504P | 2004-11-02 | 2004-11-02 | |
| PCT/IB2005/003312 WO2006048751A1 (en) | 2004-11-02 | 2005-10-21 | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518904A JP2008518904A (ja) | 2008-06-05 |
| JP2008518904A5 true JP2008518904A5 (enExample) | 2008-10-09 |
Family
ID=35538878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538541A Pending JP2008518904A (ja) | 2004-11-02 | 2005-10-21 | ６−［２−（メチルカルバモイル）フェニルスルファニル］−３−ｅ−［２−（ピリジン−２−イル）エテニル］インダゾールの多形体形態 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060094763A1 (enExample) |
| EP (1) | EP1819696A1 (enExample) |
| JP (1) | JP2008518904A (enExample) |
| KR (1) | KR20070060145A (enExample) |
| AR (1) | AR051945A1 (enExample) |
| AU (1) | AU2005300317A1 (enExample) |
| BR (1) | BRPI0517924A (enExample) |
| CA (1) | CA2586177A1 (enExample) |
| IL (1) | IL182580A0 (enExample) |
| MX (1) | MX2007005273A (enExample) |
| RU (1) | RU2007116150A (enExample) |
| TW (1) | TW200630356A (enExample) |
| WO (1) | WO2006048751A1 (enExample) |
| ZA (1) | ZA200702976B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2608952A1 (en) * | 2005-05-19 | 2006-11-23 | Dwayne Thomas Friesen | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| EP4249063A3 (en) * | 2007-04-05 | 2024-03-13 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals |
| TW201328725A (zh) | 2011-09-30 | 2013-07-16 | Pfizer | Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物 |
| CA2855211A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
| EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| CN104140414B (zh) * | 2013-05-07 | 2018-12-11 | 江苏豪森药业集团有限公司 | 阿昔替尼晶型的制备方法 |
| WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
| SI3102605T1 (sl) | 2014-02-04 | 2019-04-30 | Pfizer Inc. | Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka |
| CA2955676A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| BR112017018234A2 (pt) | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| WO2016178150A1 (en) * | 2015-05-05 | 2016-11-10 | Shilpa Medicare Limited | Novel polymorphs of axitinib |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| WO2018065938A1 (en) | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| WO2020003196A1 (en) * | 2018-06-28 | 2020-01-02 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of axitinib |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| WO2020212253A1 (en) | 2019-04-18 | 2020-10-22 | Synthon B.V. | Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt |
| WO2020225413A1 (en) | 2019-05-09 | 2020-11-12 | Synthon B.V. | Pharmaceutical composition comprising axitinib |
| PT3884929T (pt) | 2020-03-25 | 2023-08-09 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor da tirosina cinase |
| CN113943271B (zh) * | 2020-07-15 | 2023-11-14 | 鲁南制药集团股份有限公司 | 一种阿昔替尼晶型及其制备方法 |
| CN112174933A (zh) * | 2020-08-07 | 2021-01-05 | 天津理工大学 | 一种阿西替尼富马酸盐的新晶型及其制备方法 |
| CN114685436B (zh) * | 2020-12-25 | 2022-12-02 | 鲁南制药集团股份有限公司 | 阿昔替尼糖精共晶水合物 |
| CN114685437B (zh) * | 2020-12-25 | 2022-12-09 | 鲁南制药集团股份有限公司 | 阿昔替尼与糖精共晶 |
| CN114685431B (zh) * | 2020-12-26 | 2022-11-29 | 鲁南制药集团股份有限公司 | 一种阿昔替尼柠檬酸盐晶型 |
| CN114685433B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 一种阿昔替尼香草酸共晶盐及其制备 |
| CN114685435B (zh) * | 2020-12-28 | 2023-01-31 | 鲁南制药集团股份有限公司 | 阿昔替尼马来酸盐晶型及其制备 |
| CN114685432B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 阿昔替尼盐晶型及其制备方法 |
| CN114685438B (zh) * | 2020-12-28 | 2023-06-13 | 鲁南制药集团股份有限公司 | 一种阿昔替尼苹果酸新盐 |
| AU2023227442A1 (en) | 2022-03-03 | 2024-09-12 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| EP4282415A1 (en) | 2022-05-26 | 2023-11-29 | Genepharm S.A. | A stable tablet composition of axitinib |
| AU2024251447A1 (en) | 2023-04-11 | 2025-08-21 | Ocular Therapeutix, Inc. | Ocular implant comprising axitinib polymorph iv |
| KR20250108329A (ko) | 2024-01-08 | 2025-07-15 | (주)유케이케미팜 | 엑시티닙의 제조방법 |
| WO2025157389A1 (en) | 2024-01-22 | 2025-07-31 | Iomx Therapeutics Ag | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors |
| KR20250150872A (ko) * | 2024-04-12 | 2025-10-21 | 주식회사 스카이테라퓨틱스 | 액시티닙의 신규 분자 회합체 |
| KR102838026B1 (ko) * | 2024-04-30 | 2025-07-28 | 주식회사 스카이테라퓨틱스 | 액시티닙 신규 분자 회합체를 포함하는 점안 조성물 및 이의 제조방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
-
2005
- 2005-10-21 JP JP2007538541A patent/JP2008518904A/ja active Pending
- 2005-10-21 CA CA002586177A patent/CA2586177A1/en not_active Abandoned
- 2005-10-21 AU AU2005300317A patent/AU2005300317A1/en not_active Abandoned
- 2005-10-21 KR KR1020077010040A patent/KR20070060145A/ko not_active Ceased
- 2005-10-21 BR BRPI0517924-6A patent/BRPI0517924A/pt not_active IP Right Cessation
- 2005-10-21 RU RU2007116150/04A patent/RU2007116150A/ru not_active Application Discontinuation
- 2005-10-21 WO PCT/IB2005/003312 patent/WO2006048751A1/en not_active Ceased
- 2005-10-21 EP EP05796896A patent/EP1819696A1/en not_active Withdrawn
- 2005-10-21 MX MX2007005273A patent/MX2007005273A/es not_active Application Discontinuation
- 2005-10-31 US US11/264,493 patent/US20060094763A1/en not_active Abandoned
- 2005-11-01 TW TW094138274A patent/TW200630356A/zh unknown
- 2005-11-01 AR ARP050104569A patent/AR051945A1/es unknown
-
2007
- 2007-04-11 ZA ZA200702976A patent/ZA200702976B/xx unknown
- 2007-04-16 IL IL182580A patent/IL182580A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007116150A (ru) | Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола | |
| JP6008937B2 (ja) | １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法 | |
| EP1027050B1 (en) | 1,3-thiazoles as adenosine a3 receptor antagonists for the treatment of allergy, asthma and diabetes | |
| JP5546717B2 (ja) | アリピプラゾール結晶質形態を調製する方法 | |
| DE60033028T2 (de) | 5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
| EP2178870B1 (en) | Indole and indazole compounds as an inhibitor of cellular necrosis | |
| JP2023002516A5 (enExample) | ||
| WO2006036024A1 (ja) | プロトンポンプ阻害薬 | |
| EP2297104A1 (de) | 2-alkoxy-substituierte dicyanopyridine und ihre verwendung | |
| JP2008543860A5 (enExample) | ||
| AU2017238504A1 (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | |
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| JP2014505107A (ja) | 過誤腫性腫瘍細胞を阻害する方法 | |
| JP2007532560A5 (enExample) | ||
| JP2019516749A5 (enExample) | ||
| JP2008525419A (ja) | Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤 | |
| DE102010030688A1 (de) | Substituierte Dicyanopyridine und ihre Verwendung | |
| CN104098570A (zh) | 替卡格雷晶型及其制备方法和用途 | |
| JP3539926B2 (ja) | 抗ウイルス性ピリミジンジオン誘導体及びそれらの製造方法 | |
| KR101601999B1 (ko) | 2-옥소-알킬-1-피페라진-2-온의 유도체, 그의 제조 방법 및 그의 치료 용도 | |
| JP2022553833A5 (enExample) | ||
| CN101679367A (zh) | 脑梗塞治疗药剂 | |
| CA2772499A1 (en) | Polymorphic forms of manidipine | |
| CN110054584A (zh) | 1-芳基-3-{4-[(吡啶-2-基甲基)硫基]苯基}脲类化合物及应用 | |
| JP2010540440A5 (enExample) |